Brain metabolic correlates of cerebrospinal fluid beta-amyloid 42 and tau in alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 27, Issue 5, 2009, Pages 474-480

  Vukovich, Ruth ^a,b   Perneczky, Robert ^a,b   Drzezga, Alexander ^b   Förstl, Hans ^b   Kurz, Alexander ^b   Riemenschneider, Matthias ^a,b,c  

^a Department of Psychiatry and Psychotherapy   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

18F FDG positron emission tomography; Alzheimer's disease; Beta amyloid; Cerebrospinal fluid; Dementia; Glucose metabolism; Statistical parametric mapping; Tau protein

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; FLUORODEOXYGLUCOSE F 18; GLUCOSE; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; CEREBROSPINAL FLUID ANALYSIS; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GLUCOSE METABOLISM; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; TEMPORAL CORTEX;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BRAIN CHEMISTRY; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; NEURONS; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TAU PROTEINS;

EID: 65549131590     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218080     Document Type: Article

References (32)

1. Braak H, Braak E: Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239-259.
2. Thal DR, Rub U, Orantes M, Braak H: Phases of a beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791-1800.
3. Iqbal K, Grundke-Iqbal I: Mechanism of Alzheimer neurofibrillary degeneration and the formation of tangles. Mol Psychiatry 1997;2:178-180.
4. Irvine GB, El-Agnaf OM, Shankar GM, Walsh DM: Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. Mol Med 2008;14:451-464.
5. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H: Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CF. Neurology 1999;52:1555-1562.
6. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A: Cerebrospinal fluid tau and beta-amyloid 42proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 2002;59:1729-1734.
7. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P: Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734-746.
8. Sestini S: The neural basis of functional neuroimaging signal with positron and single-photon emission tomography. Cell Mol Life Sci 2007;64:1778-1784.
9. 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med 2008;49:390-398.
10. Tsolaki M, Sakka V, Gerasimou G, Dimacopoulos N, Chatzizisi O, Fountoulakis KN, Kyriazis G, Papanastasiou J, Kazis A: Correlation of rCBF (SPECT), CSF tau, and cognitive function in patients with dementia of the Alzheimer's type, other types of dementia, and control subjects. Am J Alzheimers Dis Other Demen 2001;16:21-31.
11. 1-42, but not tau have positive correlation with brain glucose metabolism in humans. Neurosci Lett 1999;273:203-207.
12. Haense C, Buerger K, Kalbe E, Drzezga A, Teipel SJ, Markiewicz P, Herholz K, Heiss WD, Hampel H: CSF total and phosphorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer's disease. 2008;15:1155-1162.
13. 18F-fluoro-2-deoxy-D-glucose positron emission tomography findings in patients with mild cognitive impairment. Biol Psychiatry 2004;56:279-283.
14. Ceravolo R, Borghetti D, Kiferle L, Tognoni G, Giorgetti A, Neglia D, Sassi N, Frosini D, Rossi C, Petrozzi L, Siciliano G, Murri L: CSF phosporylated tau protein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer's disease. Brain Res Bull 2008;76:80-84.
15. Selkoe DJ: Alzheimer's disease is a synaptic failure. Science 2002;298:789-791.
16. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L: Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA 1999;96:3228-3233.
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 1984;34:939-944.
18. Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, Schwaiger M, Kurz A: Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 2003;30:1104-1113.
19. Morris JC, Mohs RC, Rogers H, Fillenbaum G, Heyman A: Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol Bull 1988;24:641-652.
20. Folstein MF, Folstein SE, McHugh PR: 'Mini-Mental State': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
21. Vandermeeren M, Mercken M, Vanmechelen E, Six J, van de Voorde A, Martin JJ, Cras P: Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993;61:1828-1834.
22. Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E: Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 2000;7:245-258.
23. Perneczky R, Drzezga A, Diehl-Schmid J, Schmid G, Wohlschlager A, Kars S, Grimmer T, Wagenpfeil S, Monsch A, Kurz A: Schooling mediates brain reserve in Alzheimer's disease: findings of fluoro-deoxyglucose-positron emission tomography. J Neurol Neurosurg Psychiatry 2006;77:1060-1063.
24. Genovese C, Lazar N, Nichols T: Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage 2002;15:870-878.
25. Perneczky R, Drzezga A, Boecker H, Wagenpfeil S, Forstl H, Kurz A, Haussermann P: Right prefrontal hypometabolism predicts delusions in dementia with Lewy bodies. Neurobiol Aging 2008, E-pub ahead of print.
26. Fox P, Lancester J: Neuroscience on the net. Science 1994;266:994-996.
27. Ishii K, Imamura T, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, Hashimoto M, Hirono N, Shimomura T, Mori E: Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease. Neurology 1998;51:125-130.
28. Perneczky R, Wagenpfeil S, Komossa K, Grimmer T, Diehl J, Kurz A: Mapping scores onto stages: Mini-Mental State Examination and Clinical Dementia Rating. Am J Geriatr Psychiatry 2006;14:139-144.
29. Parameshwaran K, Dhanasekaran M, Suppiramaniam V: Amyloid beta peptides and glutamatergic synaptic dysregulation. Exp Neurol 2008;210:7-13.
30. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM: Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid abeta42in humans. Ann Neurol 2006;59:512-519.
31. Moossy J, Zubenko GS, Martinez AJ, Rao GR, Kopp U, Hanin I: Lateralization of brain morphologic and cholinergic abnormalities in Alzheimer's disease. Arch Neurol 1989;46:639-642.
32. Kadir A, Andreasen N, Almkvist O, Wall A, Forsberg A, Engler H, Hagman G, Larksater M, Winblad B, Zetterberg H, Blennow K, Langstrom B, Nordberg A: Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol 2008;63:621-631.